Kiora CFO has 911 KPRX shares withheld for taxes

Kiora Pharmaceuticals CFO Melissa Tosca reported a small insider transaction involving company common stock.

Rhea-AI Filing Summary

Kiora Pharmaceuticals CFO Melissa Tosca reported a small insider transaction involving company common stock. On July 1, 2026, 911 shares were disposed of at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to satisfy tax obligations rather than sold on the open market. Following this transaction, Tosca directly holds 26,064 shares of Kiora Pharmaceuticals common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 911 shares

Exercise Price or Tax Liability 1 txn

Insider Tosca Melissa

Role CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	911	$2.66	$2K

Holdings After Transaction: Common Stock — 26,064 shares (Direct)

Key Figures

Tax-withholding shares: 911 shares Price per share: $2.66 per share Shares held after transaction: 26,064 shares +1 more

4 metrics

Tax-withholding shares 911 shares Common Stock used for tax-withholding disposition on July 1, 2026

Price per share $2.66 per share Value assigned to shares delivered for tax obligations

Shares held after transaction 26,064 shares Direct Kiora Pharmaceuticals common stock holdings by CFO after Form 4 event

Transaction type Tax-withholding disposition (Code F) Payment of tax liability by delivering securities

Key Terms

Form 4, tax-withholding disposition, Common Stock, Payment of exercise price or tax liability by delivering securities

4 terms

Form 4 regulatory

"This is a routine, compensation-related Form 4 event."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

tax-withholding disposition financial

"911 shares were disposed of at $2.66 per share as a tax-withholding disposition"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Common Stock financial

"911 Kiora Pharmaceuticals common shares were delivered at $2.66 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Payment of exercise price or tax liability by delivering securities financial

"categorized as payment of a tax liability by delivering securities instead of a traditional market sale"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KPRX CFO Melissa Tosca report?

Melissa Tosca reported a tax-related share disposition. On July 1, 2026, 911 Kiora Pharmaceuticals common shares were delivered at $2.66 per share to cover tax obligations, rather than sold in an open-market trade. This is a routine, compensation-related Form 4 event.

How many KPRX shares were involved in the latest Form 4 filing?

The filing shows 911 Kiora Pharmaceuticals shares affected. These common stock shares were used in a tax-withholding disposition at $2.66 per share, categorized as payment of a tax liability by delivering securities instead of a traditional market sale.

Does the KPRX CFO still hold shares after this Form 4 transaction?

Yes, the CFO continues to hold KPRX shares. After the July 1, 2026 tax-withholding disposition, Melissa Tosca directly owns 26,064 shares of Kiora Pharmaceuticals common stock, indicating she retains a meaningful equity stake in the company.

Was the KPRX Form 4 transaction an open-market sale or a tax withholding?

The transaction was a tax-withholding disposition, not an open-market sale. The Form 4 describes the code F event as payment of a tax liability by delivering 911 Kiora Pharmaceuticals shares at $2.66 per share.

What does transaction code F mean in the KPRX Form 4 filing?

Code F indicates a tax-withholding or exercise-price payment. In this case, 911 Kiora Pharmaceuticals common shares were delivered at $2.66 each to satisfy tax obligations, rather than reflecting a discretionary buy or sell in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:47 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tosca Melissa

(Last) (First) (Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CALIFORNIA 92024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		F		911	D	$2.66	26,064	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Net Share settlement, shares withheld for employee tax obligation upon vesting of restricted stock.

	/s/ Melissa Tosca	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)